Lattice Biologics Ltd. (LBLTF)

Lattice Biologics Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016
Net Income	-0.95	-1.48	-1.01	-1.23	-1.52	-7.85
Depreciation & Amortization	0.18	0.38	0.2	0.2	0.22	0.48
Loss (Gain) From Sale of Assets	-	-	-	-	-	0
Asset Writedown & Restructuring Costs	-	-	-	-	0.3	-
Stock-Based Compensation	-	-	0.02	0.15	0.3	1.39
Provision & Write-off of Bad Debts	-	-	0.02	-	-	0.08
Other Operating Activities	-0.8	-0.04	0.27	-0.37	-2.32	1.35
Change in Accounts Receivable	0.07	-0.03	-0.11	0.05	0.21	0.26
Change in Inventory	0.06	0.18	0.78	0.36	0.35	0.76
Change in Accounts Payable	1.28	1.5	0.04	1.21	1.71	1.61
Change in Other Net Operating Assets	0.02	0.02	-0.05	-0.11	0.01	-0.21
Operating Cash Flow	-0.13	0.54	0.16	0.26	-0.75	-2.13
Operating Cash Flow Growth	-	231.72%	-38.80%	-	-	-
Capital Expenditures	-0.57	-0.59	-0.05	-0.23	-0.03	-0.05
Investing Cash Flow	-0.57	-0.59	-0.05	-0.23	-0.03	-0.05
Long-Term Debt Issued	-	0.32	-	-	0.03	0.43
Total Debt Issued	0.16	0.32	-	-	0.03	0.43
Long-Term Debt Repaid	-	-0.22	-0.1	-0.05	-0.25	-0.55
Total Debt Repaid	-0.11	-0.22	-0.1	-0.05	-0.25	-0.55
Net Debt Issued (Repaid)	0.05	0.1	-0.1	-0.05	-0.22	-0.13
Issuance of Common Stock	-	-	-	-	0.55	2.31
Other Financing Activities	-	-	-	-	0.41	-
Financing Cash Flow	0.05	0.1	-0.1	-0.05	0.74	2.18
Net Cash Flow	0.01	0.04	0.01	-0.01	-0.03	0
Free Cash Flow	-0.7	-0.06	0.11	0.03	-0.77	-2.18
Free Cash Flow Growth	-	-	229.28%	-	-	-
Free Cash Flow Margin	-44.92%	-2.27%	5.01%	2.88%	-28.28%	-57.75%
Free Cash Flow Per Share	-0.01	-0.00	0.00	-	-0.01	-0.04
Cash Interest Paid	0.06	0.06	0.06	0.01	0.03	0.17
Levered Free Cash Flow	-	-1.07	0.21	0.37	-1.72	1.52
Unlevered Free Cash Flow	-	-0.42	0.55	0.66	-1.43	2.17
Change in Working Capital	1.44	1.67	0.67	1.51	2.27	2.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.